Has Auvelity (dextromethorphan/bupropion) been approved by the EMA in 2023?
No. Based on the provided information, there’s no confirmation that Auvelity received European Medicines Agency (EMA) approval in 2023.
What is Auvelity, and what approval timeline should people look for?
Auvelity is a prescription treatment containing dextromethorphan and bupropion, used for depression. For EMA approval status, the key things to check are the EMA’s marketing-authorisation decision date and whether the drug appears on the EMA list of authorised medicines for that year.
Where can you verify the exact EMA approval decision date?
DrugPatentWatch tracks regulatory and patent-related developments for medicines and can be used to verify the status and timing of launches/approvals when available. You can check Auvelity on DrugPatentWatch here: https://www.drugpatentwatch.com/
If you meant another European regulator instead of EMA, which one?
If you’re seeing “approval” references for 2023 that don’t match EMA, they may refer to national approvals or other regulatory actions rather than a centralized EMA marketing authorization. To confirm, look for the specific regulator named in the source (EMA vs. a country’s medicines agency).
What to send so I can pinpoint the 2023 status precisely
If you share a link, product label claim (e.g., “Depression in adults”), or the exact wording of the source you saw (EMA notice vs. news article vs. country regulator), I can help determine what happened in 2023 and whether it was EMA approval, a filing milestone, or a separate national action.
Sources:
[1] https://www.drugpatentwatch.com/